Literature DB >> 8996209

Absorption and excretion of undegradable peptides: role of lipid solubility and net charge.

J R Pappenheimer1, M L Karnovsky, J E Maggio.   

Abstract

Absorption and excretion of undegradable peptides were investigated with use of octapeptides synthesized from D-amino acids. D-Tyrosine was included in each peptide to permit labeling with 125I, D-glutamic acid or D-lysine were included to vary net electric charge and D-serine or D-leucine were included to vary lipid solubility. Peptides were administered parenterally or orally to normal rats drinking 5% glucose or maltose. Forty-five percent of a lipid-insoluble, negatively charged octapeptide added to the drinking fluid in milligram quantities was absorbed from the intestine and excreted intact in urine; 90% of this peptide was recovered in urine after parenteral injection. In contrast, lipophilic D-octapeptides were largely excreted in feces, even after subcutaneous injection; the amounts excreted in feces were correlated with oil/aqueous partition coefficients. Evidence is presented that lipophilic peptides entering liver cells combine with bile salts to form hydrophilic complexes that are secreted rapidly at high concentration in bile. At physiological concentrations of bile salts (5-40 mM) and nanomolar concentrations of peptide the binding is so complete that these undegradable peptides are rapidly cleared from liver to duodenal fluid in association with the bile salts. After reaching the ileum the bile salts are reabsorbed to blood, leaving the original lipophilic peptides to be excreted in the feces from which they can be extracted, purified and identified by high-pressure liquid chromatography. These mechanisms are discussed in relation to a) the paracellular absorption of peptides and other solutes by solvent drag and b) the delivery and fate of biologically active peptides.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8996209

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

1.  Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.

Authors:  Brett D Welch; J Nicholas Francis; Joseph S Redman; Suparna Paul; Matthew T Weinstock; Jacqueline D Reeves; Yolanda S Lie; Frank G Whitby; Debra M Eckert; Christopher P Hill; Michael J Root; Michael S Kay
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

2.  Intestinal absorption of miltefosine: contribution of passive paracellular transport.

Authors:  Cécile Ménez; Marion Buyse; Christophe Dugave; Robert Farinotti; Gillian Barratt
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

3.  Potent D-peptide inhibitors of HIV-1 entry.

Authors:  Brett D Welch; Andrew P VanDemark; Annie Heroux; Christopher P Hill; Michael S Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

4.  An intestinal paracellular pathway biased toward positively-charged macromolecules.

Authors:  Khaled Almansour; Alistair Taverner; Jerrold R Turner; Ian M Eggleston; Randall J Mrsny
Journal:  J Control Release       Date:  2018-09-06       Impact factor: 9.776

5.  Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux.

Authors:  David Meriwether; Dawoud Sulaiman; Alan Wagner; Victor Grijalva; Izumi Kaji; Kevin J Williams; Liqing Yu; Spencer Fogelman; Carmen Volpe; Steven J Bensinger; G M Anantharamaiah; Ishaiahu Shechter; Alan M Fogelman; Srinivasa T Reddy
Journal:  J Lipid Res       Date:  2016-05-19       Impact factor: 5.922

6.  Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally.

Authors:  Mohamad Navab; Srinivasa T Reddy; G M Anantharamaiah; Satoshi Imaizumi; Greg Hough; Susan Hama; Alan M Fogelman
Journal:  J Lipid Res       Date:  2011-03-28       Impact factor: 5.922

7.  Curvature sensing MARCKS-ED peptides bind to membranes in a stereo-independent manner.

Authors:  Lei Yan; Armando Jerome de Jesus; Ryo Tamura; Victoria Li; Kui Cheng; Hang Yin
Journal:  J Pept Sci       Date:  2015-04-08       Impact factor: 1.905

8.  Characterization of a proteolytically stable D-peptide that suppresses herpes simplex virus 1 infection: implications for the development of entry-based antiviral therapy.

Authors:  Dinesh Jaishankar; Abraam M Yakoub; Anita Bogdanov; Tibor Valyi-Nagy; Deepak Shukla
Journal:  J Virol       Date:  2014-11-26       Impact factor: 5.103

9.  Interferon-γ activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapy.

Authors:  Thomas R Diraimondo; Cornelius Klöck; Chaitan Khosla
Journal:  J Pharmacol Exp Ther       Date:  2012-01-06       Impact factor: 4.030

10.  Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure.

Authors:  Martin Leduc; Xin Hou; David Hamel; Melanie Sanchez; Christiane Quiniou; Jean-Claude Honoré; Olivier Roy; Ankush Madaan; William Lubell; Daya R Varma; Joseph Mancini; François Duhamel; Krishna G Peri; Vincent Pichette; Nikolaus Heveker; Sylvain Chemtob
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.